Cancer Research and Treatment

Original Articles

Palliative medicine

Development of a Prediction Model for Delirium in Hospitalized Patients with Advanced Cancer: Eun Hee Jung, Shin Hye Yoo, Si Won Lee, Beodeul Kang, Yu Jung Kim; Cancer Res Treat. 2024;56(4):1277-1287. Published online February 26, 2024; DOI: https://doi.org/10.4143/crt.2023.1243

Abstract PDF Supplementary Material PubReader ePub

Purpose
Delirium is a common neurocognitive disorder in patients with advanced cancer and is associated with poor clinical outcomes. As a potentially reversible phenomenon, early recognition of delirium by identifying the risk factors demands attention. We aimed to develop a model to predict the occurrence of delirium in hospitalized patients with advanced cancer.
Materials and Methods
This retrospective study included patients with advanced cancer admitted to the oncology ward of four tertiary cancer centers in Korea for supportive cares and excluded those discharged due to death. The primary endpoint was occurrence of delirium. Sociodemographic characteristics, clinical characteristics, laboratory findings, and concomitant medication were investigated for associating variables. The predictive model developed using multivariate logistic regression was internally validated by bootstrapping.
Results
From January 2019 to December 2020, 2,152 patients were enrolled. The median age of patients was 64 years, and 58.4% were male. A total of 127 patients (5.9%) developed delirium during hospitalization. In multivariate logistic regression, age, body mass index, hearing impairment, previous delirium history, length of hospitalization, chemotherapy during hospitalization, blood urea nitrogen and calcium levels, and concomitant antidepressant use were significantly associated with the occurrence of delirium. The predictive model combining all four categorized variables showed the best performance among the developed models (area under the curve 0.831, sensitivity 80.3%, and specificity 72.0%). The calibration plot showed optimal agreement between predicted and actual probabilities through internal validation of the final model.
Conclusion
We proposed a successful predictive model for the risk of delirium in hospitalized patients with advanced cancer.

Citations

Citations to this article as recorded by

Association Between Blood Urea Nitrogen and Delirium in Critically Ill Elderly Patients Without Kidney Diseases: A Retrospective Study and Mendelian Randomization Analysis
Yipeng Fang, Xiaohong Tang, Ying Gao, Hui Xie, Yuehao Shen, Min Peng, Jie Liu, Yunfei Zhang, Yan Cui, Keliang Xie
CNS Neuroscience & Therapeutics.2025;[Epub] CrossRef

1,754 View
119 Download
1 Web of Science
1 Crossref

Breast cancer

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy: Eun-Gyeong Lee, Dong-Eun Lee, Hyun hee Kim, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Heejung Chae, Sung Hoon Sim, Keun Seok Lee, Youngmee Kwon, So-Youn Jung; Cancer Res Treat. 2023;55(2):542-550. Published online September 8, 2022; DOI: https://doi.org/10.4143/crt.2022.834

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods
We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results
Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion
AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker.

Citations

Citations to this article as recorded by

The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response
Di Ai, Eliel N Arrey, Lauren M Postlewait, Yuan Gao, Xiaoxian Li
Histopathology.2025;[Epub] CrossRef
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Athina Stravodimou, Ioannis A. Voutsadakis
Expert Review of Anticancer Therapy.2024; 24(3-4): 117. CrossRef
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
Miseon Lee, Tae-Kyung Yoo, Byung Joo Chae, Ahwon Lee, Yoon Jin Cha, Jieun Lee, Sung Gwe Ahn, Jun Kang
Scientific Reports.2024;[Epub] CrossRef
Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma
Adil Aziz Khan, Sana Ahuja, Kiruthikasri G., Sufian Zaheer
Indian Journal of Surgical Oncology.2024; 15(4): 802. CrossRef
Biomarkers and translational research approaches in breast cancer—an update
Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch
memo - Magazine of European Medical Oncology.2023; 16(1): 42. CrossRef
Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang
Discover Oncology.2023;[Epub] CrossRef

5,341 View
177 Download
6 Web of Science
6 Crossref

Lung and Thoracic cancer

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Hyojin Kim, Hyun Jung Kwon, Eun Sun Kim, Soohyeon Kwon, Kyoung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jong Seok Lee, Jin-Haeng Chung; Cancer Res Treat. 2022;54(2):424-433. Published online July 7, 2021; DOI: https://doi.org/10.4143/crt.2021.583

Abstract PDF Supplementary Material PubReader ePub

Purpose
Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of TMB and GEP to predict the immunotherapy response in patients with non–small cell lung cancer (NSCLC) and assessed if this combination can improve predictive power compared to that when used individually.
Materials and Methods
This retrospective cohort study included 30 patients with NSCLC who received immune checkpoint inhibitors (ICI) therapy at the Seoul National University Bundang Hospital. programmed cell death-ligand-1 (PD-L1) protein expression was assessed using immunohistochemistry, and TMB was measured by targeted deep sequencing. Gene expression was determined using NanoString nCounter analysis for the PanCancer IO360 panel, and enrichment analysis were performed.
Results
Eleven patients (36.7%) showed a durable clinical benefit (DCB), whereas 19 (63.3%) showed no durable benefit (NDB). TMB and enrichment scores (ES) showed significant differences between the DCB and NDB groups (p=0.044 and p=0.017, respectively); however, no significant correlations were observed among TMB, ES, and PD-L1. ES was the best single biomarker for predicting DCB (area under the curve [AUC], 0.794), followed by TMB (AUC, 0.679) and PD-L1 (AUC, 0.622). TMB and ES showed the highest AUC (0.837) among other combinations (AUC [TMB and PD-L1], 0.777; AUC [PD-L1 and ES], 0.763) and was similar to that of all biomarkers used together (0.832).
Conclusion
The combination of TMB and ES may be an effective predictive tool to identify patients with NSCLC patients who would possibly benefit from ICI therapies.

Citations

Citations to this article as recorded by

Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins
Chuanhao Tang, Zaizai Dong, Shi Yan, Bing Liu, Zhiying Wang, Long Cheng, Feng Liu, Hong Sun, Yimeng Du, Lu Pan, Yuhao Zhou, Zhiyuan Jin, Libo Zhao, Nan Wu, Lingqian Chang, Xiaojie Xu
Biosensors and Bioelectronics.2025; 267: 116748. CrossRef
Exploring the ferroptosis-related gene lipocalin 2 as a potential biomarker for sepsis-induced acute respiratory distress syndrome based on machine learning
Jiayi Zhan, Junming Chen, Liyan Deng, Yining Lu, Lianxiang Luo
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(4): 167101. CrossRef
Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial
Cheol-Kyu Park, Ha Ra Jun, Hyung-Joo Oh, Ji-Young Lee, Hyun-Ju Cho, Young-Chul Kim, Jeong Eun Lee, Seong Hoon Yoon, Chang Min Choi, Jae Cheol Lee, Sung Yong Lee, Shin Yup Lee, Sung-Min Chun, In-Jae Oh
Cells.2023; 12(9): 1246. CrossRef
Unveiling the role of regulatory T cells in the tumor microenvironment of pancreatic cancer through single-cell transcriptomics and in vitro experiments
Wei Xu, Wenjia Zhang, Dongxu Zhao, Qi Wang, Man Zhang, Qiang Li, Wenxin Zhu, Chunfang Xu
Frontiers in Immunology.2023;[Epub] CrossRef
Facilitating “Omics” for Phenotype Classification Using a User-Friendly AI-Driven Platform: Application in Cancer Prognostics
Uraquitan Lima Filho, Tiago Alexandre Pais, Ricardo Jorge Pais
BioMedInformatics.2023; 3(4): 1071. CrossRef
Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review)
Mo Cheng, Xiufeng Zheng, Jing Wei, Ming Liu
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef

8,103 View
221 Download
12 Web of Science
6 Crossref

Prospective Evaluation of the Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Negative Axillary Conversion after Neoadjuvant Chemotherapy: Hy-De Lee, Sung Gwe Ahn, Seung Ah Lee, Hak Min Lee, Joon Jeong; Cancer Res Treat. 2015;47(1):26-33. Published online August 29, 2014; DOI: https://doi.org/10.4143/crt.2013.208

Abstract PDF PubReader ePub

Purpose
Tumor response to neoadjuvant chemotherapy (NAC) may adversely affect the identification and accuracy rate of sentinel lymph node biopsy (SLNB). This study was conducted to evaluate the feasibility of SLNB in node-positive breast cancer patients with negative axillary conversion after NAC. Materials and Methods Ninety-six patients with positive nodes at presentation were prospectively enrolled. 18Fluorodeoxyglucose-positron emission tomography (18F-FDG PET) and ultrasonography were performed before and after NAC. A metastatic axillary lymph node was defined as positive if it was positive upon both 18F-FDG PET and ultrasonography, while it was considered negative if it was negative upon both 18F-FDG PET and ultrasonography. Results After NAC, 55 cases (57.3%) became clinically node-negative, while 41 cases (42.7%) remained node-positive. In the entire cohort, the sentinel lymph node (SLN) identification and false-negative rates were 84.3% (81/96) and 18.4% (9/49), respectively. In the negative axillary conversion group, the results of SLNB showed an 85.7% (48/55) identification rate and 16.7% (4/24) false-negative rate. Conclusion For breast cancer patients with clinically positive nodes at presentation, it is difficult to conclude whether the SLN accurately represents the metastatic status of all axillary lymph nodes, even after clinically negative node conversion following NAC.

Citations

Citations to this article as recorded by

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature
Alexandra Maria Lazar, Mario-Demian Mutuleanu, Paula Monica Spiridon, Cristian Ioan Bordea, Tatiana Lucia Suta, Alexandru Blidaru, Mirela Gherghe
Diagnostics.2023; 13(18): 3000. CrossRef
AGO-Empfehlungen zur operativen Therapie der Axilla nach neoadjuvanter Chemotherapie: Update 2021
Michael Friedrich, Thorsten Kühn, Wolfgang Janni, Volkmar Müller, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Christian Jackisch, David Krug, Ute-Susann Albert, Ingo Bauerfeind, Jens Blohmer, Wilfried Budach, Peter Dall, Eva M. Fallenberg, Peter A
Senologie - Zeitschrift für Mammadiagnostik und -therapie.2022; 19(01): 56. CrossRef
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review
Juan C. Vázquez, Antonio Piñero, Francisco J. de Castro, Ana Lluch, Miguel Martín, Agustí Barnadas, Emilio Alba, Álvaro Rodríguez-Lescure, Federico Rojo, Julia Giménez, Ivan Solá, Maria J. Quintana, Xavier Bonfill, Gerard Urrutia, Pedro Sánchez-Rovira
Clinical and Translational Oncology.2022; 25(2): 417. CrossRef
Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data
Shi-Qian Lin, Nguyen-Phong Vo, Yu-Chun Yen, Ka-Wai Tam
Annals of Surgical Oncology.2022; 29(5): 3038. CrossRef
Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,578 patients
Siyang Cao, Xia Liu, Junwei Cui, Xiaoling Liu, Jieyu Zhong, Zijian Yang, Desheng Sun, Wei Wei
The Breast.2021; 59: 256. CrossRef
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Michael Friedrich, Thorsten Kühn, Wolfgang Janni, Volkmar Müller, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Christian Jackisch, David Krug, Ute-Susann Albert, Ingo Bauerfeind, Jens Blohmer, Wilfried Budach, Peter Dall, Eva M. Fallenberg, Peter A
Geburtshilfe und Frauenheilkunde.2021; 81(10): 1112. CrossRef
Therapiealgorithmen für das Mammakarzinom
J.-U. Blohmer, A. Schneeweiss, I. Bauerfeind, T. Fehm, V. Müller, C. Thomssen, I. Witzel, A. Wöckel, W. Janni
Der Onkologe.2021; 27(12): 1165. CrossRef
Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
Chihwan Cha, Sung Gwe Ahn, Dooreh Kim, Janghee Lee, Soeun Park, Soong June Bae, Jee Ye Kim, Hyung Seok Park, Seho Park, Seung Il Kim, Byeong‐Woo Park, Joon Jeong
International Journal of Cancer.2021; 149(8): 1585. CrossRef
The Accuracy of Sentinel Lymph Node Biopsy Following Neoadjuvant Chemotherapy in Clinically Node Positive Breast Cancer Patients: A Single Institution Experience
Hossein Yahyazadeh, Maria Hashemian, Mojtaba Rajabpour, Saina Aminmozaffari, Maryam Zaree, Ahmad R Mafi, Hossein Pourtavakoli, Narges Sistany Allahabadi, Marzieh Beheshti
International Journal of Cancer Management.2018;[Epub] CrossRef
A survey of current surgical treatment of early stage breast cancer in China
Xin Zhang, Ying Wang
Oncoscience.2018; 5(7-8): 239. CrossRef
Predictive Factors for Nonsentinel Lymph Node Metastasis in Patients With Positive Sentinel Lymph Nodes After Neoadjuvant Chemotherapy: Nomogram for Predicting Nonsentinel Lymph Node Metastasis
Jai Min Ryu, Se Kyung Lee, Ji Young Kim, Jonghan Yu, Seok Won Kim, Jeong Eon Lee, Se Hwan Han, Yong Sik Jung, Seok Jin Nam
Clinical Breast Cancer.2017; 17(7): 550. CrossRef

21,784 View
127 Download
12 Web of Science
11 Crossref

Usefulness of Change of Telomerase Activity as a Predictive Assay for Radiation Response: Hong Gyun Wu, Young Jue Kim, Il Han Kim, Charn Il Park, Sung Whan Ha; J Korean Cancer Assoc. 2000;32(6):1109-1114.

Abstract PDF: PURPOSE
A sensitive predictive assay is necessary to determine the total radiation dose according to sensitivity of individual cancer cell lines. This study is performed to determine whether the radiation sensitivity is correlated with the changes in telomerase activity after irradiation.
MATERIALS AND METHODS
Two colorectal cancer cell lines with different radiation sensitivity were used. In order to confirm the difference in radiation sensitivity, we used a calorimetric assay. Telomerase activities were measured using the PCR-based telomeric repeat amplification protocol (TRAP).
RESULTS
We confirmed the difference in radiation sensitivity between NCI-H630 and NCI-H716. Survival fractions at 2 Gy were 0.836 for NCI-H630 and 0.317 for NCI-H716. Telomerase activity increased after irradiation with NCI-H630, which was more resistant to radiation, whereas telomerase activity decreased with NCI-H730. But dose-dependent change of telomerase activity was not confirmed.
CONCLUSION
Our results suggested that telomerase activity change after irradiation could be used as a predictive assay for radiation response. Further studies with different cell lines and tumor tissues are necessary.

2,252 View
17 Download

First
Prev
Page of 1
Next
Last

Search